Abstract
P093 - Plasma glycosaminoglycan scores in early stage renal cell carcinoma
Highlights
Introduction & ObjectivesNo diagnostic blood biomarker for renal cell carcinoma (RCC) is currently used in the clinical routine
Using a systems biology approach, we previously developed a score based on circulating glycosaminoglycans (GAGs) that detected metastatic clear cell renal cell carcinoma (RCC) with 92.6%, 93.7%, and 100% accuracy vs. healthy subjects using either plasma, urine, or combined measurements in a validation cohort (Gatto et al, 2016, Cell Reports)
Participants were enrolled as a consecutive series at the Memorial Sloan Kettering Cancer Center, New York City, United States between 2011 and 2014
Summary
Introduction & ObjectivesNo diagnostic blood biomarker for RCC is currently used in the clinical routine. Plasma glycosaminoglycan scores in early stage renal cell carcinoma Of Biology And Biological Engineering, Gothenburg, Sweden, 2Memorial Sloan Kettering Cancer Center, Department of Urology, New York City, United States of America, 3University of Modena and Reggio Emilia, Dept.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
